Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11111494 Compositions for modulating Ataxin 2 expression

Patent 11111494 was granted and assigned to Ionis Pharmaceuticals on September, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

All edits

Edits on 14 Mar, 2024
"update inverses"
Golden AI profile picture
Golden AI
edited on 14 Mar, 2024
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
‌
US Patent 11926825 Compounds and methods for reducing ATXN2 expression
0
Edits on 12 Dec, 2023
"Add patent abstract"
Golden AI profile picture
Golden AI
edited on 12 Dec, 2023
Edits made to:
Article (+389 characters)
Article

Patent abstract

Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotropic sclerosis (ALS), and parkinsonism.

Edits on 7 Dec, 2023
"update inverses"
Golden AI profile picture
Golden AI
edited on 7 Dec, 2023
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
‌
US Patent 11834660 Compositions for modulating Ataxin 2 expression
0
Edits on 24 Nov, 2023
"Edit from table cell"
Megan Gustafson profile picture
Megan Gustafson
edited on 24 Nov, 2023
Edits made to:
Infobox (+1/-1 properties)
Infobox
Current Assignee
00
Current Assignee
Ionis Pharmaceuticals
Ionis Pharmaceuticals
"Edit from table cell"
Megan Gustafson profile picture
Megan Gustafson
edited on 24 Nov, 2023
Edits made to:
Infobox (+1/-1 properties)
Infobox
Patent Applicant
00
Patent Applicant
Ionis Pharmaceuticals
Ionis Pharmaceuticals
Edits on 21 May, 2023
"Remove website redirecting to Patent Public Search front page"
Golden AI profile picture
Golden AI
edited on 21 May, 2023
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
https://pdfpiw.uspto.gov/.piw?Docid=1111149400
Edits on 25 Apr, 2023
"Entity importer update"
Golden AI profile picture
Golden AI
edited on 25 Apr, 2023
Infobox
Is a
Patent
Patent
0
Patent Applicant
0
Current Assignee
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
111114940
Date of Patent
September 7, 2021
0
Patent Application Number
201904170
Date Filed
April 17, 2019
0
Official Website
https://pdfpiw.uspto.gov/.piw?Docid=111114940
Edits on 24 Sep, 2022
"Entity importer update"
Golden AI profile picture
Golden AI
edited on 24 Sep, 2022
Infobox
Is a
Patent
Patent
0
Patent Applicant
0
Current Assignee
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
111114940
Date of Patent
September 7, 2021
0
Patent Application Number
201904170
Date Filed
April 17, 2019
0
Official Website
https://pdfpiw.uspto.gov/.piw?Docid=111114940
Edits on 6 Jun, 2022
"Entity importer update"
Golden AI profile picture
Golden AI
edited on 6 Jun, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
https://pdfpiw.uspto.gov/.piw?Docid=11111494
Edits on 17 Sep, 2021
"Created via: Entity Importer"
Golden AI profile picture
Golden AI
created this topic on 17 Sep, 2021
Edits made to:
Infobox (+8 properties)
‌

 US Patent 11111494 Compositions for modulating Ataxin 2 expression

Infobox
Is a
Patent
Patent
Patent applicant
Current assignee
Patent jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent number
11111494
Date of patent
September 7, 2021
Patent application number
20190417
Date Filed
April 17, 2019

Find more entities like US Patent 11111494 Compositions for modulating Ataxin 2 expression

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.